

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PALIPERIDONE PALMITATE INJECTION RECEIVES MARKETING APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Paliperidone Palmitate Injection (strengths including: (1) 0.75ml: 75mg; (2) 1.0ml: 100mg; (3) 1.5ml: 150mg (calculated as $C_{23}H_{27}FN_4O_3$)) (the “**Product**”), a second-generation long-acting antipsychotic injection independently developed by the Group, has received marketing approval from the National Medical Products Administration of the People’s Republic of China, and is indicated for the treatment of schizophrenia in both acute and maintenance phases.

Compared with traditional schizophrenia drugs, the Product requires only once-monthly administration and has a rapid onset of action after dosing, without the need for supplemental oral medication, making it suitable for the treatment of patients in the acute phase. Furthermore, the once-monthly administration regimen significantly improves patients’ medication adherence, prevents missed doses, and effectively reduces the rates of disease relapse and rehospitalisation.

The Product has been listed as a recommended medication in authoritative domestic and international clinical guidelines, including the *Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition)*. It is a preferred treatment option for patients with schizophrenia who have poor adherence and a high risk of relapse, offering high clinical and pharmacoeconomic value.

The approval of the Product will further enrich the Group's product portfolio in the psychiatric and neurological therapeutic area. The Group will continue to dedicate itself to developing more drugs with high clinical value to provide better treatment options for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 24 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.